Membrane Transition Temperature Determines Cisplatin Response.
Cisplatin is a classical chemotherapeutic agent used in treating several forms of cancer including head and neck. However, cells develop resistance to the drug in some patients through a range of mechanisms, some of which are poorly understood. Using isolated plasma membrane vesicles as a model system, we present evidence suggesting that cisplatin induced resistance may be due to certain changes in the bio-physical properties of plasma membranes. Giant plasma membrane vesicles (GPMVs) isolated from cortical cytoskeleton exhibit a miscibility transition between a single liquid phase at high temperature and two distinct coexisting liquid phases at low temperature. The temperature at which this transition occurs is hypothesized to reflect the magnitude of membrane heterogeneity at physiological temperature. We find that addition of cisplatin to vesicles isolated from cisplatin-sensitive cells result in a lowering of this miscibility transition temperature, whereas in cisplatin-resistant cells such treatment does not affect the transition temperature. To explore if this is a cause or consequence of cisplatin resistance, we tested if addition of cisplatin in combination with agents that modulate GPMV transition temperatures can affect cisplatin sensitivity. We found that cells become more sensitive to cisplatin when isopropanol, an agent that lowers GPMV transition temperature, was combined with cisplatin. Conversely, cells became resistant to cisplatin when added in combination with menthol that raises GPMV transition temperatures. These data suggest that changes in plasma membrane heterogeneity augments or suppresses signaling events initiated in the plasma membranes that can determine response to cisplatin. We postulate that desired perturbations of membrane heterogeneity could provide an effective therapeutic strategy to overcome cisplatin resistance for certain patients.
Department of Biophysics, University of Michigan, Ann Arbor, Michigan, United States of America.
Krishnan
K
Raghunathan
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Aarif
A
Ahsan
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Dipankar
D
Ray
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Mukesh K
MK
Nyati
Department of Biophysics, University of Michigan, Ann Arbor, Michigan, United States of America.
Sarah L
SL
Veatch
D019840:2-Propanol / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects* / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology*; D003599:Cytoskeleton / Q000378:metabolism; D006801:Humans; D021962:Membrane Microdomains / Q000187:drug effects* / Q000378:metabolism; D013696:Temperature; D044366:Transition Temperature
D000970:Antineoplastic Agents; D019840:2-Propanol; D002945:Cisplatin